Publications by authors named "Andrew A Finnerty"
J Am Soc Nephrol
October 2023
Article Synopsis
- Mesenchymal stromal cells (MSCs) show potential as a new therapy for diabetic kidney disease (DKD), but clinical trials have faced challenges.
- In a phase 1b/2a trial involving 16 adults with type 2 diabetes, a low dose of MSCs (ORBCEL-M) was found to be safe and well-tolerated, with no serious adverse events linked to the treatment.
- Compared to a placebo group, those receiving ORBCEL-M experienced a significantly slower decline in kidney function, suggesting the need for further studies on this therapy.
